Macrogenics (MGNX) Stock Price, Quote & News

Company Profile

MacroGenics, Inc., a clinical-stage biopharmaceutical company, discovers, develops, manufactures, and commercializes antibody-based therapeutics to treat cancer in the United States. The company's product pipeline includes lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4 for the treatment of mCRPC and docetaxel that is in phase 2 clinical trials, as well as for the treatment of platinum-resistant ovarian cancer and clear cell gynecologic cancer which ha...

Industry: Biotechnology

Sector: Healthcare

Phone: 301 251 5172

Fax: 301 251 5321

Website: www.macrogenics.com

Address:

9704 Medical Center Drive, Rockville, United States

StockScanners Feb. 27 at 4:39 AM

$MGNX reached 2.02

0 · Reply

Budman10 Feb. 26 at 7:39 PM

$MGNX For what it is worth

1 · Reply

PSDL75 Feb. 26 at 7:34 PM

$MGNX since seeing $2

0 · Reply

FloFloFloFlo Feb. 26 at 6:40 PM

$MGNX why aren’t more people coming to this ticker to discuss the seemingly all over the place and nonsensical price action here?! 🧐

0 · Reply

StockScanners Feb. 26 at 3:33 AM

$MGNX keep watch if this holds above 1.88

0 · Reply

Budman10 Feb. 25 at 9:58 PM

$MGNX Company has approx $3 per share cash on hand. Way undervalued. doesnt take into account any enterprise value.

1 · Reply

PandaSwingz Feb. 25 at 7:13 PM

$DRTS $FRMI $COIN $MGNX •••

1 · Reply

Budman10 Feb. 25 at 2:46 PM

$MGNX Can someone explain why the share price is even higher after the bad news?🤷

2 · Reply

FloFloFloFlo Feb. 24 at 3:45 PM

$MGNX can someone explain to me why the share price has mostly bounced back already this morning?

2 · Reply

OpenOutcrier Feb. 24 at 2:07 PM

$MGNX (-8.6% pre) MacroGenics (MGNX) Faces FDA Setback with Partial Hold on Lorige https://ooc.bz/l/94457

0 · Reply

MacroGenics to Participate in Upcoming Investor Conferences

Feb 23, 2026, 6:14 PM EST - 3 days ago

MacroGenics Announces Pausing of Enrollment of New Study Participants in LINNET Trial

Nov 25, 2025, 4:05 PM EST - 3 months ago

MacroGenics to Participate in the 8th Annual Evercore Healthcare Conference

Nov 12, 2025, 4:01 PM EST - 3 months ago

MacroGenics Reports Third Quarter 2025 Financial Results and Provides Update on Corporate Progress

Nov 6, 2025, 4:30 PM EST - 4 months ago

MacroGenics to Participate in the Stifel 2025 Healthcare Conference

Sep 2, 2025, 4:30 PM EDT - 6 months ago

MacroGenics to Present at H.C. Wainwright 27th Annual Global Investment Conference

Aug 14, 2025, 4:01 PM EDT - 7 months ago

MacroGenics Reports Second Quarter 2025 Financial Results and Highlights Key Strategic Priorities

Aug 13, 2025, 4:01 PM EDT - 7 months ago

MacroGenics Appoints Eric Risser as President and Chief Executive Officer

Jun 11, 2025, 6:32 PM EDT - 9 months ago

MacroGenics: Working On That Road To Recovery

Jun 10, 2025, 7:00 AM EDT - 9 months ago

MacroGenics and Sagard Healthcare Partners Enter into ZYNYZ® Royalty Purchase Agreement

Jun 3, 2025, 4:30 PM EDT - 9 months ago

MacroGenics to Present at the Goldman Sachs 46th Annual Global Healthcare Conference 2025

May 13, 2025, 4:01 PM EDT - 10 months ago

MacroGenics Provides Update on Corporate Progress and First Quarter 2025 Financial Results

May 6, 2025, 4:30 PM EDT - 10 months ago

MacroGenics Announces Date of First Quarter 2025 Financial Results

May 1, 2025, 4:30 PM EDT - 10 months ago

MacroGenics to Participate in Upcoming Investor Conference

Mar 20, 2025, 7:09 PM EDT - 1 year ago

MacroGenics, Inc. (MGNX) Q4 2024 Earnings Call Transcript

Mar 6, 2025, 7:30 AM EST - 1 year ago

MacroGenics Announces Date of Fourth Quarter and Full Year 2024 Financial Results Conference Call

Feb 27, 2025, 2:08 PM EST - 1 year ago

MacroGenics: Stacking Up A Lot Of Headwinds

Nov 5, 2024, 7:01 PM EST - 1 year ago

MacroGenics, Inc. (MGNX) Q2 2024 Earnings Call Transcript

Nov 5, 2024, 4:01 PM EST - 1 year ago

MacroGenics Provides Update on Corporate Progress, Third Quarter 2024 Financial Results

Oct 30, 2024, 7:30 AM EDT - 1 year ago

MacroGenics Announces Leadership Transition

Oct 29, 2024, 4:30 PM EDT - 1 year ago

MacroGenics Announces Date of Third Quarter 2024 Financial Results Conference Call

Oct 25, 2024, 5:15 PM EDT - 1 year ago

Rigrodsky Law, P.A. Is Investigating MacroGenics, Inc. On Behalf of Shareholders

Oct 22, 2024, 7:30 AM EDT - 1 year ago

MacroGenics Enters Into Agreement With TerSera Therapeutics for the Sale of MARGENZA®

Sep 24, 2024, 12:57 PM EDT - 1 year ago

Shareholders of MacroGenics, Inc. Should Contact The Gross Law Firm Before September 24, 2024 to Discuss Your Rights – MGNX

Sep 24, 2024, 10:30 AM EDT - 1 year ago

MGNX Investors Have Opportunity to Join MacroGenics, Inc. Fraud Investigation with the Schall Law Firm

Sep 23, 2024, 11:00 AM EDT - 1 year ago

MacroGenics Inc Is Being Sued For Violating Securities Laws And Shareholders With Losses Are Encouraged To Contact The Schall Law Firm

Sep 22, 2024, 11:09 AM EDT - 1 year ago

MacroGenics (MGNX) Accused of Misleading Investors Over Cancer Drug Trial - Hagens Berman

Sep 21, 2024, 11:00 AM EDT - 1 year ago

MacroGenics Inc Is Being Sued For Violating Securities Laws And Shareholders With Losses Are Urged To Reach Out To The Schall Law Firm

Sep 19, 2024, 11:00 AM EDT - 1 year ago

MacroGenics Inc Is Being Sued For Violating Securities Laws And Shareholders Are Urged To Contact The Schall Law Firm

Sep 19, 2024, 9:57 AM EDT - 1 year ago

DEADLINE REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of MacroGenics

Sep 19, 2024, 5:45 AM EDT - 1 year ago

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of September 24, 2024 in MacroGenics Lawsuit - MGNX

Sep 17, 2024, 11:23 AM EDT - 1 year ago

MGNX Deadline: Rosen Law Firm Urges MacroGenics, Inc. (NASDAQ: MGNX) Stockholders with Large Losses in Excess of $100K to Contact the Firm for Information About Their Rights

Sep 17, 2024, 11:04 AM EDT - 1 year ago

Hospice Dynamix Welcomes Industry Veteran Rob Stoltz as Chief Strategy Officer

Sep 17, 2024, 11:00 AM EDT - 1 year ago

MacroGenics Inc May Have Violated Securities Laws And Shareholders With Losses Are Urged To Contact The Schall Law Firm About A Suit

StockScanners Feb. 27 at 4:39 AM

$MGNX reached 2.02

0 · Reply

Budman10 Feb. 26 at 7:39 PM

$MGNX For what it is worth

1 · Reply

PSDL75 Feb. 26 at 7:34 PM

$MGNX since seeing $2

0 · Reply

FloFloFloFlo Feb. 26 at 6:40 PM

$MGNX why aren’t more people coming to this ticker to discuss the seemingly all over the place and nonsensical price action here?! 🧐

0 · Reply

StockScanners Feb. 26 at 3:33 AM

$MGNX keep watch if this holds above 1.88

0 · Reply

Budman10 Feb. 25 at 9:58 PM

$MGNX Company has approx $3 per share cash on hand. Way undervalued. doesnt take into account any enterprise value.

1 · Reply

PandaSwingz Feb. 25 at 7:13 PM

$DRTS $FRMI $COIN $MGNX •••

1 · Reply

Budman10 Feb. 25 at 2:46 PM

$MGNX Can someone explain why the share price is even higher after the bad news?🤷

2 · Reply

FloFloFloFlo Feb. 24 at 3:45 PM

$MGNX can someone explain to me why the share price has mostly bounced back already this morning?

2 · Reply

OpenOutcrier Feb. 24 at 2:07 PM

$MGNX (-8.6% pre) MacroGenics (MGNX) Faces FDA Setback with Partial Hold on Lorige https://ooc.bz/l/94457

0 · Reply

focafoca99 Feb. 24 at 7:06 AM

$MGNX faces a partial FDA clinical hold on LINNET, I expect delays and higher development costs

0 · Reply

PMD777 Feb. 23 at 11:38 PM

$MGNX welp sub $1 now?

1 · Reply

Jkpga Feb. 23 at 11:34 PM

$MGNX more wonderful news

0 · Reply

StockNews_Live Feb. 23 at 11:14 PM

$MGNX he FDA has placed a partial clinical hold on MacroGenics' Phase 2 LINNET study of lorigerlimab in gynecologic cancer due to safety events in four patients. The study will not enroll new patients unti…

0 · Reply

MarketWarfare Feb. 23 at 5:28 PM

$MGNX Gilead Sciences has struck a deal to buy Arcellx for $7.8 billion to take full control of a CAR-T cell therapy that is on the cusp of approval. Arcellx partnered with Gilead to develop the BCMA-directed CAR-T anitocabtagene autoleucel (anito-cel) in 2022. Gilead invested in Arcellx as part of the agreement and, having invested again when amending the deal in 2023, owns 11.5% of the company. With Gilead on the hook for $530 million in milestones for anito-cel, analysts had speculated about a potential buyout.

1 · Reply

Budman10 Feb. 20 at 7:50 PM

$MGNX 67k volume indicates no more institutional dumping. No retail interest either. Good to see that management received all their stock options. Keep it up team, us shareholders are so happy with your efforts this past year

1 · Reply

Budman10 Feb. 20 at 3:46 AM

$MGNX I’m convinced the game is to drive every retail investor out. Only then will something positive happen to the stock price. If leveraged you are gone or going soon

0 · Reply

BillionerOfKing Feb. 18 at 12:07 PM

$MGNX Current Stock Price: $1.71 Contracts to trade: $1.5 MGNX Feb 20 2026 Call Entry: $0.32 Exit: $0.50 ROI: 58% Hold ~26 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts

0 · Reply

biolover Feb. 14 at 4:58 PM

$VKTX where the F $MRK CEO from all that. Someone told me he used to run furniture selling company prior to MRK CFO. His problem is Dean Li. he takes about science based deals and then did a nebulizer acquisition.. His $70 B pipeline revenues only in his mind Wnd the sad thing, market believes that . Anyway, he will still likely acquire my other company $MGNX as his H7B3 ADC too toxic.

0 · Reply

Budman10 Feb. 14 at 2:44 AM

$MGNX as I suspected another one bites the dust. Hello management keep it up. We shareholders love the lack of your transparency.

0 · Reply

MarketWarfare Feb. 12 at 3:33 PM

$MGNX the radio silence is absolutely ridiculous. Gotta give us something. Why is there even an IR department? An 11 person board of directors is also crazy work.

0 · Reply

Estimize Feb. 12 at 12:09 PM

Wall St is expecting -0.29 EPS for $MGNX Q4 [Reporting 02/19 AMC] http://www.estimize.com/intro/mgnx?chart=historical&metric_name=eps&utm_c

0 · Reply

Market Cap	121.46M
Revenue (ttm)	149.96M
Net Income (ttm)	-66.97M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-44.66%
Debt to Equity Ratio	0.00

Volume	327,492
Avg Vol	1,175,856
Day's Range	N/A - N/A
Shares Out	63.26M
Stochastic %K	94%
Beta	1.50
Analysts	Sell
Price Target	$3.40